Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 293,881 shares at $10.43 ($3.0M) on 2025-04-10, disclosed to the SEC on 2025-04-11.
Open-market purchase of $3.0M RNAC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.43 | 7,342 | $69K | 2.3% |
| 2 | $9.43 | 7,342 | $69K | 2.3% |
| 3 | $9.43 | 41,604 | $392K | 13.1% |
| 4 | $9.43 | 41,604 | $392K | 13.1% |
| 5 | $9.95 | 31 | $308 | 0.0% |
| 6 | $9.95 | 178 |
| $2K |
| 0.1% |
| 7 | $10.43 | 7,966 | $83K | 2.8% |
| 8 | $10.43 | 7,966 | $83K | 2.8% |
| 9 | $10.43 | 45,144 | $471K | 15.7% |
| 10 | $10.43 | 45,144 | $471K | 15.7% |
| 11 | $10.92 | 3,451 | $38K | 1.3% |
| 12 | $10.92 | 609 | $7K | 0.2% |
| 13 | $10.77 | 36,338 | $391K | 13.1% |
| 14 | $10.77 | 36,338 | $391K | 13.1% |
| 15 | $10.77 | 6,412 | $69K | 2.3% |
| 16 | $10.77 | 6,412 | $69K | 2.3% |
| Total | $10.20 avg | 293,881 | $3.0M | 100% |
| Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |
| RNAC | BUY | 2025-01-15 | $660K | — | Filing → |